sorafenib has been researched along with 2-aminopyrimidine in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (2-aminopyrimidine) | Trials (2-aminopyrimidine) | Recent Studies (post-2010) (2-aminopyrimidine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 119 | 0 | 92 |
| Protein | Taxonomy | sorafenib (IC50) | 2-aminopyrimidine (IC50) |
|---|---|---|---|
| Botulinum neurotoxin type A | Clostridium botulinum | 4.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Awasthi, BP; Chaudhary, P; Guragain, D; Jee, JG; Jeong, BS; Kim, JA | 1 |
1 other study(ies) available for sorafenib and 2-aminopyrimidine
| Article | Year |
|---|---|
Synthesis and anti-hepatocellular carcinoma activity of aminopyridinol-sorafenib hybrids.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Molecular Docking Simulation; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Xenograft Model Antitumor Assays | 2021 |